ScholarIQanswers from OpenAlex & ORCID
Maxime Dougados
ResearcherPublications, citations & collaboration network
Maxime Dougados is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Maxime Dougados have?
ScholarIQindexed works
Maxime Dougados has 631 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Maxime Dougados have?
ScholarIQcitation count
Maxime Dougados has 48,463 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Maxime Dougados?
ScholarIQh-index
Maxime Dougados has an h-index of 101 in OpenAlex.
What is the i10-index of Maxime Dougados?
ScholarIQi10-index
Maxime Dougados has an i10-index of 319 in OpenAlex.
What is the OpenAlex record for Maxime Dougados?
ScholarIQopenalex
The OpenAlex for Maxime Dougados is on the source record.
What are the most-cited papers on Maxime Dougados?
ScholarIQmost cited works
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
Jasvinder A. Singh, Daniel E. Fürst, Aseem Bharat, Jeffrey R. Curtis, Arthur F. Kavanaugh, Joel M. Kremer, Larry W. Moreland, James R. O’Dell, Kevin Winthrop, Timothy Beukelman, S. Louis Bridges, W. Winn Chatham, Harold E. Paulus, María E. Suarez‐Almazor, Claire Bombardier, Maxime Dougados, Dinesh Khanna, Charles M. King, Amye Leong, Eric L. Matteson, John T. Schousboe, Eileen Moynihan, Karen S. Kolba, Archana Jain, Elizabeth R. Volkmann, Harsh Agrawal, Sangmee Bae, Amy S. Mudano, Nivedita M. Patkar, Kenneth G. Saag
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks
Stanley Cohen, Paul Emery, Maria Greenwald, Maxime Dougados, Richard Furie, Mark C. Genovese, Edward Keystone, J. Loveless, Gerd‐Rüdiger Burmester, Matthew Cravets, E. Hessey, T Shaw, Mark C. Totoritis
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
Josef S Smolen, Ferdinand C. Breedveld, Gerd R Burmester, Vivian P. Bykerk, Maxime Dougados, Paul Emery, Tore K Kvien, M Victoria Navarro-Compán, Susan Oliver, Monika Schoels, Marieke Voshaar, Tanja Stamm, Michaela Stoffer, Tsutomu Takeuchi, Daniel Aletaha, José Luís Andreu, Martin Aringer, Martin Bergman, Neil Betteridge, Hans Bijlsma, Harald Burkhardt, Mario Cardiel, Bernard Combe, Patrick Durez, João Eurico Fonseca, Alan Gibofsky, Juan J. Gómez‐Reino, W. Graninger, Pekka Hannonen, Boulos Haraoui, Marios Kouloumas, Robert Landewé, E. Martín‐Mola, Peter Nash, Mikkel Østergaard, Andrew J.K. Östör, P. Scott Richards, Tuulikki Sokka‐Isler, Carter Thorne, Athanasios G. Tzioufas, Ronald van Vollenhoven, M. De Wit, Désirée van der Heijde
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis
Cédric Lukas, Robert Landewé, Joachim Sieper, Maxime Dougados, John C. Davis, Joseph M. Braun, S van der Linden, Désirée van der Heijde
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
Joseph M. Braun, Rosaline van den Berg, Xenofon Baraliakos, Heinrich Boehm, R Burgos-Vargas, Eduardo Collantes‐Estévez, Hanne Dagfinrud, Ben A. C. Dijkmans, Maxime Dougados, Paul Emery, Pál Géher, M. Hammoudeh, RD Inman, Merryn Jongkees, MA Khan, Uta Kiltz, Tore K Kvien, Marjatta Leirisalo‐Repo, Walter P. Maksymowych, Ignazio Olivieri, Karel Pavelká, J. Sieper, Ewa Stanisławska‐Biernat, Daniel Wendling, Salih Özgöçmen, C van Drogen, Barend J. van Royen, D. van der Heijde